Qaialdo Eiropas Savienība - latviešu - EMA (European Medicines Agency)

qaialdo

nova laboratories ireland limited - spironolactone - edema; heart failure; liver cirrhosis; ascites; nephrotic syndrome; hyperaldosteronism; essential hypertension - antihypertensives and diuretics in combination - in the management of refractory oedema associated with congestive cardiac failure; hepatic cirrhosis with ascites and oedema, malignant ascites, nephrotic syndrome, diagnosis and treatment of primary aldosteronism, essential hypertension. neonates, children and adolescents should only be treated under guidance of a paediatric specialist (see sections 5. 1 un 5.

Intuniv Eiropas Savienība - latviešu - EMA (European Medicines Agency)

intuniv

takeda pharmaceuticals international ag ireland branch - guanfacine hydrochloride - uzmanības deficīta traucējumi ar hiperaktivitāti - antiadrenergic agents, centrally acting, antihypertensives, - intuniv is indicated for the treatment of attention deficit hyperactivity disorder (adhd) in children and adolescents 6 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. intuniv jāizmanto kā daļa no visaptverošas adhd ārstēšana programmas, parasti, tostarp psiholoģisko, izglītības un sociālo pasākumi.

Adempas Eiropas Savienība - latviešu - EMA (European Medicines Agency)

adempas

bayer ag - riociguat - hipertensija, plaušu slimība - antihypertensives for pulmonary arterial hypertension - chronic thromboembolic pulmonary hypertension (cteph)adempas is indicated for the treatment of adult patients with who functional class (fc) ii to iii withinoperable cteph,persistent or recurrent cteph after surgical treatment,to improve exercise capacity. pulmonary arterial hypertension (pah)adultsadempas, as monotherapy or in combination with endothelin receptor antagonists, is indicated for the treatment of adult patients with pulmonary arterial hypertension (pah) with who functional class (fc) ii to iii to improve exercise capacity. efektivitāte ir redzams pao iedzīvotājiem, tostarp aetiologies, idiopātiska vai iedzimtības pao, vai arī pao, kas saistīta ar saistaudu slimības. paediatricsadempas is indicated for the treatment of pah in paediatric patients aged less than 18 years of age and body weight ≥ 50 kg with who functional class (fc) ii to iii in combination with endothelin receptor antagonists.

Prescanden HCT 8 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

prescanden hct 8 mg/12,5 mg tabletes

sandoz d.d., slovenia - candesartanum cilexetilum, hydrochlorothiazidum - tabletes - 8 mg/12,5 mg

Prescanden HCT 16 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

prescanden hct 16 mg/12,5 mg tabletes

sandoz d.d., slovenia - candesartanum cilexetilum, hydrochlorothiazidum - tabletes - 16 mg/12,5 mg

Prescanden HCT 32 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

prescanden hct 32 mg/12,5 mg tabletes

sandoz d.d., slovenia - candesartanum cilexetilum, hydrochlorothiazidum - tabletes - 32 mg/12,5 mg

Prescanden HCT 32 mg/25 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

prescanden hct 32 mg/25 mg tabletes

sandoz d.d., slovenia - candesartanum cilexetilum, hydrochlorothiazidum - tabletes - 32 mg/25 mg

Candisil HCT 16 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

candisil hct 16 mg/12,5 mg tabletes

laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 16 mg/12,5 mg

Candisil HCT 32 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

candisil hct 32 mg/12,5 mg tabletes

laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 32 mg/12,5 mg

Candisil HCT 8 mg/12,5 mg tabletes Latvija - latviešu - Zāļu valsts aģentūra

candisil hct 8 mg/12,5 mg tabletes

laboratorios liconsa, s.a., spain - candesartanum cilexetilum, hydrochlorothiazidum - tablete - 8 mg/12,5 mg